Wipro Annual Report 2025 on Form 20-F Available Online for ADS Holders
About Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading technology services and consulting company focused on building innovative solutions that address clients' most complex digital transformation needs. Leveraging our holistic portfolio of capabilities in consulting, design, engineering, and operations, we help clients realize their boldest ambitions and build future-ready, sustainable businesses. With over 230,000 employees and business partners across 65 countries, we deliver on the promise of helping our customers, colleagues, and communities thrive in an ever-changing world. For additional information, visit us at www.wipro.com.
Wipro Forward-looking Statements The forward-looking statements contained herein represent Wipro's beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro's control. Such statements include, but are not limited to, statements regarding Wipro's growth prospects, its future financial operating results, and its plans, expectations, and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry.
Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf. Click here for Media Contact Details
Submit your press release
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Cathie Wood Pours Millions into AMD, Dumps Circle After 650% Surge
June 23 - Cathie Wood's ARK Invest added to its position in Advanced Micro Devices (NASDAQ:AMD) last week, purchasing 247,753 shares worth about $31.4 million across three ETFs, according to Friday's trade disclosures. The buy was spread across the ARK Innovation (ARKK), ARK Next Generation Internet (ARKW), and ARK Fintech Innovation (ARKF) ETFs, reflecting a continued bet on AI and chipmakers. Wood also picked up 162,255 shares of Airbnb (ABNB) for around $21.4 million and 222,150 shares of Shopify (NASDAQ:SHOP) totaling roughly $23.5 million. Warning! GuruFocus has detected 3 Warning Signs with AMD. In contrast, ARK exited a sizable position in Circle Internet Group (NYSE:CRCL), selling 609,175 shares across its ETFs. The sale totaled nearly $121.6 million and marked the firm's largest trade of the day. Circle stock surged more than 20% Friday and has gained over 650% since its June 5 IPO at $31. The decision to trim the position likely reflects profit-taking after the stock's sharp rally. CRCL is the issuer of the USDC stablecoin and has drawn interest since going public. These trades suggest ARK is leaning into established tech while de-risking from names with elevated valuations after rapid gains. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Morgan Stanley Names These Two Stocks to Watch
Morgan Stanley names Chart Industries (NYSE:GTLS) and Coca-Cola (NYSE:KO) as its top H2 2025 stock picks. Chart Industries is riding high on its pending all-stock merger with Flowserve to create a $19 billion enterprise and reported Q1 revenue of $1 billion, up 5 percent year-over-year yet missing estimates by just $1.11 million. Warning! GuruFocus has detected 4 Warning Signs with GTLS. Its $1.86 non-GAAP EPS beat by $0.03, and backlog jumped to $5.14 billionthe first time above $5 billiondriven by orders in specialty products ($487.7 million) and repair, service, and leasing ($454.6 million). Morgan Stanley's Daniel Kutz argues that even conservative models still leave GTLS shares undervalued if the merger synergy targets materialize, and he assigns an Overweight rating with a $225 price target implying 58 percent upside. Coca-Cola posted Q1 revenue of $11.1 billion, down 2 percent on refranchising headwinds, but delivered 73 cents in non-GAAP EPSbeating consensus by a penny. The company's $296 billion market cap underpins its Blue Chip status, and its 2020 Fairlife acquisition (for $980 million) is fueling growth, underscored by a new $650 million facility in New York. Morgan Stanley's Dara Mohsenian highlights KO's peer-leading mid-single-digit organic sales growth, sustained pricing power, volume gains, market-share wins, and a 3 percent forward dividend yield (annualized $2.04). Why It Matters: Investors seeking both cyclical energy exposure and defensive consumer staples can balance growth and yield in a volatile market. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing
Donald Trump Jr. has joined billionaire entrepreneur Mark Cuban in publicly voicing disapproval of Sen. Elizabeth Warren (D-Mass.)'s approach to healthcare pricing. Despite their political differences, Trump Jr. and Cuban found a common point of contention in Warren's healthcare pricing strategy. They criticized the senator for not addressing the role of pharmacy benefit managers (PBMs) in escalating drug costs. Warren had previously argued that the tax system was 'rigged' because large pharmaceutical companies like Johnson & Johnson (NYSE:JNJ) often escape federal taxes while charging exorbitant prices for their drugs. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — She wrote on X saying that the "highest drug prices in the WORLD while often paying ZERO dollars in federal taxes themselves."Cuban countered this by stating that PBMs, not pharmaceutical companies, are the ones controlling and manipulating drug pricing. Trump Jr. publicly supported Cuban's viewpoint on X, despite Cuban's well-known opposition to President Trump. This unexpected agreement highlights the growing concern over the role of PBMs in healthcare pricing. PBMs have been facing increasing scrutiny from federal regulators and lawmakers due to their influence on healthcare pricing. In 2020, the Federal Trade Commission released a report criticizing PBMs for imposing unfair terms on independent pharmacies, thereby favoring large corporate pharmacies like CVS (NYSE:CVS). The public criticism from Trump Jr. and Cuban underscores the growing debate over the role of PBMs in healthcare pricing. Warren's focus on pharmaceutical companies, while not entirely misplaced, overlooks the significant influence of PBMs in determining drug prices. The Federal Trade Commission's report from last year further highlights the need for regulatory scrutiny of PBMs. As the debate continues, it remains to be seen how lawmakers will address the issue of healthcare pricing and the role of PBMs in the future. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom Image: Shutterstock/lev radin Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
